CBT-I Versus CBT-I+ACT for Youths With Insomnia and Anxiety

Sponsor
Chinese University of Hong Kong (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06156306
Collaborator
(none)
50
1
2
15.5
3.2

Study Details

Study Description

Brief Summary

Insomnia in adolescents and youth is a long-standing public health concern due to its high prevalence and association with various physical and mental health problems. Insomnia and psychiatric disorders are highly comorbid and intercorrelated in adolescents. Among all mental disorders, anxiety has been shown to be have high comorbidity with insomnia, affecting approximately 30% of individuals. CBT for insomnia (CBT-I) has been shown to be effective in improving sleep complaints and short-term improvement in mood while previous systematic reviews of interventional studies have demonstrated the effectiveness of acceptance and commitment therapy (ACT) interventions in treating insomnia, both as a primary condition and with other physical and/or mental health comorbidities. This study aims to compare the effect of CBT-I and CBT-I combined ACT in improving anxiety symptoms in youth.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: CBT-I
  • Behavioral: CBT-I combined ACT
N/A

Detailed Description

Insomnia and psychiatric disorders are highly comorbid and intercorrelated in adolescents. Among all mental disorders, anxiety has been shown to be have high comorbidity with insomnia, affecting approximately 30% of individuals. Moreover, approximately three-quarters of anxious youth also report sleep-related problems. Literature reviews have investigated the relationship and the shared underlying mechanisms between sleep and anxiety. Anxiety sensitivity and pre-sleep arousal have been found to play a critical role in difficulty initiating sleep, which is the most common insomnia symptoms in adolescent population, partially due their natural delay of circadian rhythm. The findings suggest shared neurological and cognitive features that may account for dysregulation of both sleep and affect. Management targeting both sleep and anxiety is recommended due to potentially higher treatment efficacy and cost-effectiveness.

Accumulating evidence supports the effectiveness of cognitive-behavioural therapy for insomnia (CBT-I) and acceptance and commitment therapy (ACT) for addressing sleep and mood problems in adolescents. However, Only a few studies have directly compared the effectiveness of CBT-I and ACT. Past studies have shown that both CBT-I and ACT were effective in treating insomnia in adults.

This current study aims to compare the effect of CBT-I and CBT-I combined ACT in improving anxiety symptoms in youth. The primary hypothesis is that subjects in CBT-I combined ACT will have fewer anxiety symptoms as compared to CBT-I at post-intervention and 3-month follow-up.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effectiveness of CBT-I and CBT-I Combined ACT for Insomnia and Anxiety Symptoms in Youth: A Randomised Control Trial
Anticipated Study Start Date :
Dec 15, 2023
Anticipated Primary Completion Date :
Dec 15, 2024
Anticipated Study Completion Date :
Mar 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: CBT-I

A total of 6 sessions of face-to-face group CBT-I therapy will be provided. Each session will last 90-120 mins, with each group 8-10 subjects.

Behavioral: CBT-I
The CBT-I intervention will cover sleep education, stimulus control, sleep restriction, cognitive therapy and relaxation training.

Experimental: CBT-I combined ACT

A total of 6 sessions of face-to-face group CBT-I+ACT therapy will be provided. Each session will last 90-120 mins, with each group 8-10 subjects.

Behavioral: CBT-I combined ACT
In addition to the standard CBT-I components, mindfulness, thought diary, and other ACT components will be taught in the group.

Outcome Measures

Primary Outcome Measures

  1. Severity of anxiety symptoms and severity [Baseline, Postintervention (6 weeks), and 3-month follow up]

    General Anxiety Disorder-7 (GAD-7) will be used to assess anxiety symptoms and severity.

  2. Severity of anxiety symptoms [Baseline, Postintervention (6 weeks), and 3-month follow up]

    Hospital Anxiety and Depression Scale (HADS) will be used to assess anxiety symptoms.

  3. Clinician-rated severity of anxiety symptoms [Baseline, Postintervention (6 weeks), and 3-month follow up]

    Hamilton Anxiety Rating Scale (HAM-A) will be used to assess anxiety symptoms.

Secondary Outcome Measures

  1. Severity of insomnia symptoms [Baseline, Postintervention (6 weeks), and 3-month follow up]

    Insomnia Severity Index (ISI) will be used to measure the severity of insomnia symptoms.

  2. Sleep-wake pattern [Baseline, Postintervention (6 weeks), and 3-month follow up]

    Youths will be asked to keep a sleep diary to chart their daily sleep-wake pattern including sleep duration, wakeup time, bedtime and sleep latency

  3. Daytime sleepiness [Baseline, Postintervention (6 weeks), and 3-month follow up]

    Pediatric Daytime Sleepiness Scale (PDSS) will be used to assess adolescents' daytime sleepiness.

  4. Anxiety trait [Baseline, Postintervention (6 weeks), and 3-month follow up]

    The State-Trait Anxiety Inventory (STAI) will be used to measure anxiety trait

  5. Severity of depressive symptoms [Baseline, Postintervention (6 weeks), and 3-month follow up]

    Patient Health Questionnaire 9-item (PHQ-9) will be used to measure the severity of depressive symptoms.

  6. Faulty sleep-related beliefs and cognitions [Baseline, Postintervention (6 weeks), and 3-month follow up]

    Dysfunctional Beliefs and Attitudes about Sleep Scale-16-item (DBAS-16) will be used to measure faulty sleep-related beliefs and cognitions, which are cognitive aspects typically involved in the maintenance of insomnia.

  7. Frequency of an individual practice sleep hygiene [Baseline, Postintervention (6 weeks), and 3-month follow up]

    Sleep Hygiene Practice Scale (SHPS) will be used to measure the frequency of an individual practice sleep hygiene.

  8. Psychological flexibility and experiential avoidance [Baseline, Postintervention (6 weeks), and 3-month follow up]

    Acceptance and Action Questionnaire-II (AAQ-II) is related to the underlying ACT theory to measure psychological flexibility and experiential avoidance.

  9. Individual's state of arousal [Baseline, Postintervention (6 weeks), and 3-month follow up]

    Pre-Sleep Arousal Scale (PSAS) will be used to measure individual's state of arousal as one falls asleep.

  10. Tendency to ruminate [Baseline, Postintervention (6 weeks), and 3-month follow up]

    The Ruminative Responses Scale - short version (RRS-10) is a 10-item scale on a 4-likert scale. It measures the tendency to ruminate.

  11. Major life events and hassles [Baseline, Postintervention (6 weeks), and 3-month follow up]

    The Adolescent Stress Index (ASI), which was developed using a Hong Kong student sample, will be used to measure major life events and hassles

  12. Global cognitive appraisal of one's life satisfaction [Baseline, Postintervention (6 weeks), and 3-month follow up]

    The Satisfaction With Life Scale (SWLS): SWLS is a 5-item scale on a 7-Likert scale. It measures the global cognitive appraisal of one's life satisfaction.

  13. Subjective well-being in the previous week [Baseline, Postintervention (6 weeks), and 3-month follow up]

    The International Positive and Negative Affect Schedule Short Form (IPANAS-SF) will be used to capture the subjective well-being in the previous week. It has 9 items on a 5-Likert scale with previous study demonstrating satisfactory internal consistency reliability and reasonable nomological validity in Chinese youth.

Eligibility Criteria

Criteria

Ages Eligible for Study:
15 Years to 24 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
Youth who meet the following criteria would be eligible for taking part in this trial:
  1. Chinese youth aged 15-24 years old, ii. Presence of insomnia problems as defined by insomnia severity index (ISI) using cut-off of 9, which has been locally validated cut off for detecting clinical insomnia), iii. Presence of anxiety features as defined by General Anxiety Disorder-7 (GAD-7) using cut-off of 10 for detecting clinical anxiety, iv. Ability to listen, speak, and read Chinese and Cantonese, and v. Written informed consent of participation into the study is given by youth and his/her parent's if under 18 years old; In addition, individual assent will also be obtained for subjects under age 18 years old
  2. Possession of smartphone
Exclusion Criteria:
A youth would be excluded from the study if meeting one or more of the following criteria:
  1. A clinical diagnosis of psychosis, schizophrenia, bipolar disorders, or intellectual disability ii. Having a diagnosed sleep disorder (e.g. delayed sleep phase and narcolepsy) that may potentially contribute to the disruption of sleep quantity and quality as determined by validated Diagnostic Interview for Sleep Patterns and Disorders (DISP) iii. Having a clinically significant suicidality (presence of suicidal ideation with a plan or an attempt) as assessed by The Structured Clinical Interview (SCID) iv. Currently receiving psychological treatment and/or pharmacological treatment for insomnia or anxiety disorder.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Psychiatry, the Chinese University of Hong Kong Sha Tin New Territories Hong Kong

Sponsors and Collaborators

  • Chinese University of Hong Kong

Investigators

  • Principal Investigator: Rachel Ngan Yin Chan, PhD, Department of Psychiatry, the Chinese University of Hong Kong

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
CHAN NGAN YIN, Assistant Professor, Department of Psychiatry, Chinese University of Hong Kong
ClinicalTrials.gov Identifier:
NCT06156306
Other Study ID Numbers:
  • 20230914
First Posted:
Dec 5, 2023
Last Update Posted:
Dec 5, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by CHAN NGAN YIN, Assistant Professor, Department of Psychiatry, Chinese University of Hong Kong
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 5, 2023